Is Zoledronic Acid (zoledronic acid) medically appropriate for a patient with stage IV lung adenocarcinoma (lung cancer) and osseous metastases (bone metastases)?

Medical Appropriateness Determination: Zoledronic Acid for Lung Adenocarcinoma with Bone Metastases

DETERMINATION: MEDICALLY APPROPRIATE

Zoledronic acid (Zometa) 4 mg every 12 weeks is medically appropriate for this 75-year-old male with stage IV lung adenocarcinoma and documented osseous metastases to the sacrum and left acetabulum, provided renal function is monitored and hypocalcemia is corrected prior to each infusion. 1

---

RATIONALE

Primary Indication Met

• The patient has confirmed osteolytic bone metastases from lung adenocarcinoma, documented on PET/CT showing large left acetabulum and S1 vertebral body lesions, with additional bony metastases. 1

• Zoledronic acid reduces skeletal-related events (SREs) including pathological fractures, radiation/surgery to bone, and spinal cord compression in stage IV bone metastatic disease from lung cancer with Level II evidence and Grade B recommendation. 1

• The ESMO Clinical Practice Guidelines (2018) explicitly recommend zoledronic acid in stage IV bone metastatic disease from NSCLC with Level I evidence and Grade B recommendation. 1

• Pan-Asian adapted guidelines (2019) endorsed by multiple oncology societies provide 100% agreement that zoledronic acid reduces SREs and is recommended in stage IV bone metastatic disease. 1

Evidence Supporting Efficacy

• Zoledronic acid 4 mg reduced the risk of developing SREs by 31% (hazard ratio 0.693, p=0.003) in lung cancer patients with bone metastases over 21 months of treatment. 2

• Time to first SRE was significantly delayed from 155 days with placebo to 236 days with zoledronic acid 4 mg (p=0.009). 2

• Annual incidence of SREs was reduced from 2.71 per year with placebo to 1.74 per year with zoledronic acid 4 mg (p=0.012). 2

• The American College of Chest Physicians guidelines (2013) confirm that zoledronic acid prevents skeletal-related events in NSCLC patients with bone metastases. 1

Extended Interval Dosing (Q12 Weeks)

• The requested dosing of every 12 weeks is supported by recent evidence showing that extended-interval dosing (Q12wk) had similar incidence of SREs at 1 year compared to standard Q4wk dosing (23.5% vs 23.9%, p=0.968) in lung cancer patients. 3

• Time to first SRE did not differ between Q12wk and Q4wk dosing schedules (p=0.530). 3

• Extended-interval dosing may reduce cumulative toxicity risk while maintaining efficacy, though this represents a modification from the standard FDA-approved Q3-4 week schedule. 3

Patient-Specific Appropriateness

This patient meets all criteria for treatment:

• Age ≥18 years: Patient is 75 years old. 1

• Documented osteolytic bone lesions: PET/CT from 11/2023 shows large left acetabulum and S1 vertebral body osteolytic metastases. 1

• Adequate renal function: Most recent eGFR is 63 mL/min (10/27/2025), which is above the contraindication threshold of <35 mL/min. 4, 5

• Good performance status: ECOG 1, well-appearing on exam, working out regularly. 1

• Reasonable life expectancy: Patient has excellent response to Tagrisso with stable/improved disease on 6/2025 imaging, brain metastases resolved. 1

• No current bone pain: Patient reports no bone pains and has not used oxycodone in weeks, indicating disease control but continued need for SRE prevention. 1

---

SAFETY CONSIDERATIONS AND MONITORING REQUIREMENTS

Contraindications Assessment

No absolute contraindications present:

• Renal function adequate: eGFR 63 mL/min is above the <35 mL/min contraindication threshold. 4, 5

• No documented hypocalcemia: Recent labs show normal calcium levels. 4, 5

• No known hypersensitivity: No documented allergy to zoledronic acid. 4, 5

Required Monitoring

• Serum creatinine must be measured before each dose per American Society of Clinical Oncology recommendations. 4

• Intermittent evaluation every 3-6 months for albuminuria is recommended; discontinue if unexplained albuminuria >500 mg/24 hours develops. 4

• Standard hypercalcemia-related metabolic parameters (calcium, phosphate, magnesium) should be monitored. 5

• Adequate hydration prior to each infusion is essential, particularly given the patient's age. 5

Infusion Requirements

• Single doses must not exceed 4 mg and infusion duration must be no less than 15 minutes to minimize renal toxicity risk. 5

• The requested dose of 3.5 mg is below the maximum 4 mg dose and is acceptable, though 4 mg is the standard evidence-based dose. 1, 2

Specific Risks to Monitor

Osteonecrosis of the jaw (ONJ):

• Dental examination with preventive dentistry should be completed prior to initiating bisphosphonate therapy. 5
• Patients should maintain good oral hygiene and avoid invasive dental procedures while on treatment. 5
• Risk increases with duration of exposure, though this patient is requesting only 14 treatments over approximately 3.5 years. 5

Renal deterioration:

• Preexisting renal insufficiency is a risk factor for subsequent deterioration; this patient has mild-moderate impairment (eGFR 63). 5
• Dehydration and nephrotoxic drugs should be avoided when possible. 5
• No dose adjustment needed for eGFR >60 mL/min, but close monitoring is warranted. 4, 5

Atypical femoral fractures:

• Rare but reported with bisphosphonate therapy; patients may experience thigh or groin pain weeks to months before fracture. 5
• Particularly relevant given patient's acetabular involvement; contralateral femur should be examined if femoral shaft fracture occurs. 5

---

CRITERIA ALIGNMENT

MCG Criteria A-0294 Met

All required criteria satisfied:

1. Age 18 years or older: Patient is 75 years old. ✓

2. No uncorrected hypocalcemia at time of administration: Recent labs show no hypocalcemia. ✓

3. Osteolytic bone lesions or metastases from solid tumors: PET/CT documents osteolytic lesions in left acetabulum and S1 vertebral body. ✓

4. For zoledronic acid use specifically, other solid tumors (lung cancer) are explicitly listed as an indication. ✓

Duration and Frequency

• The request for 14 treatments over approximately 3.5 years (every 12 weeks) is reasonable given:
  • Standard initial treatment is typically 1-2 years at Q3-4 week intervals. 2
  • Extended interval dosing (Q12 weeks) shows similar efficacy with potentially reduced toxicity. 3
  • Patient has stable disease on Tagrisso with excellent response, justifying continued bone-directed therapy. 1

---

CLINICAL CONTEXT

Disease Status

• Patient has excellent systemic disease control on Tagrisso (osimertinib) for EGFR L858R-mutated lung adenocarcinoma. 1

• Osseous metastases are stable on 6/25/2025 CT imaging ("unchanged osseous metastasis"). 1

• Brain metastases have resolved on serial MRI imaging (negative 2/2025,7/2025). 1

• Patient has completed 1 year of Q4-week zoledronic acid and is now transitioning to extended interval dosing, which is a reasonable de-escalation strategy. 3

Quality of Life Considerations

• Prevention of SREs directly impacts morbidity and quality of life by reducing risk of pathological fractures, need for radiation/surgery to bone, and spinal cord compression. 1, 2

• Patient is currently asymptomatic from bone metastases (no bone pain, not using opioids), making this prophylactic therapy to maintain quality of life. 1

• Extended interval dosing reduces treatment burden (fewer infusions, less time in clinic) while maintaining efficacy. 3

---

RECOMMENDATION SUMMARY

APPROVE zoledronic acid 4 mg (or 3.5 mg as requested) every 12 weeks for 14 treatments with the following conditions:

1. Verify serum creatinine/eGFR before each infusion; hold if eGFR <35 mL/min. 4, 5

2. Ensure adequate hydration prior to each infusion. 5

3. Monitor calcium, phosphate, magnesium levels periodically. 5

4. Confirm dental evaluation completed and maintain good oral hygiene. 5

5. Infuse over minimum 15 minutes to reduce renal toxicity risk. 5

6. Reassess need for continuation if disease progresses or patient develops contraindications. 1